Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, discusses a project focused on determining subgroups of multiple sclerosis (MS) patients with higher benefit for specific drug treatments. A statistical methodology that identifies patients’ characteristics indicating a benefit from a specific therapy was developed. Data from a randomized controlled trial was used in the analysis, and it was validated with data from an MS patients database. This study would advance the personalized treatment approach in MS. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Dr Maria Pia Sormani received consulting fees from Biogen, Novartis, Roche, Merck, Sanofi, Celgene, Geneuro, Immunic & Medday.